Cargando…

The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients

Introduction Fabry disease is a metabolic storage disorder that causes disorders in multiple organs including the brain. Data regarding the prevalence of the disease among the Saudi stroke population is scarce. Hence, tests for the same are not conducted on a regular basis when investigating stroke...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhazzaa, Mohammed A, Mujtaba, Ahmed, Aljohani, Mohammed A, Alqarni, Fatimah, Alsharif, Roaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450207/
https://www.ncbi.nlm.nih.gov/pubmed/32864243
http://dx.doi.org/10.7759/cureus.9415
_version_ 1783574769274191872
author Alhazzaa, Mohammed A
Mujtaba, Ahmed
Aljohani, Mohammed A
Alqarni, Fatimah
Alsharif, Roaa
author_facet Alhazzaa, Mohammed A
Mujtaba, Ahmed
Aljohani, Mohammed A
Alqarni, Fatimah
Alsharif, Roaa
author_sort Alhazzaa, Mohammed A
collection PubMed
description Introduction Fabry disease is a metabolic storage disorder that causes disorders in multiple organs including the brain. Data regarding the prevalence of the disease among the Saudi stroke population is scarce. Hence, tests for the same are not conducted on a regular basis when investigating stroke of uncertain cause. Our study aimed to provide insight into whether testing for Fabry disease is justifiable in cryptogenic stroke patients who have no other features of the disease. Method This was a prospective study conducted at a single stroke center. We included young patients between the ages of 18 and 55 years who had confirmed and unexplained ischemic or hemorrhagic insults. Alpha-galactosidase enzyme testing was conducted in all suspected cases. Further genetic testing was performed in patients with abnormal enzyme results. Result A total of 51 patients met the inclusion criteria. The mean age was 42 years. All the included patients completed a workup of ischemia or hemorrhage. All cases had no clear etiology of their vascular events. All included patients lacked classic systemic manifestations of Fabry disease. We identified one case of borderline low α-galactosidase A (GLA) enzyme level. However, GLA genetic testing did not reveal any Fabry disease-related mutation. The study did not identify any subject with confirmed Fabry disease. Conclusion In this single-center study, we found that Fabry disease had a low prevalence among Saudi cryptogenic stroke patients who lack other systemic manifestations. Hence, Fabry testing is not generally considered in routine workup related to cryptogenic stroke.
format Online
Article
Text
id pubmed-7450207
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-74502072020-08-28 The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients Alhazzaa, Mohammed A Mujtaba, Ahmed Aljohani, Mohammed A Alqarni, Fatimah Alsharif, Roaa Cureus Neurology Introduction Fabry disease is a metabolic storage disorder that causes disorders in multiple organs including the brain. Data regarding the prevalence of the disease among the Saudi stroke population is scarce. Hence, tests for the same are not conducted on a regular basis when investigating stroke of uncertain cause. Our study aimed to provide insight into whether testing for Fabry disease is justifiable in cryptogenic stroke patients who have no other features of the disease. Method This was a prospective study conducted at a single stroke center. We included young patients between the ages of 18 and 55 years who had confirmed and unexplained ischemic or hemorrhagic insults. Alpha-galactosidase enzyme testing was conducted in all suspected cases. Further genetic testing was performed in patients with abnormal enzyme results. Result A total of 51 patients met the inclusion criteria. The mean age was 42 years. All the included patients completed a workup of ischemia or hemorrhage. All cases had no clear etiology of their vascular events. All included patients lacked classic systemic manifestations of Fabry disease. We identified one case of borderline low α-galactosidase A (GLA) enzyme level. However, GLA genetic testing did not reveal any Fabry disease-related mutation. The study did not identify any subject with confirmed Fabry disease. Conclusion In this single-center study, we found that Fabry disease had a low prevalence among Saudi cryptogenic stroke patients who lack other systemic manifestations. Hence, Fabry testing is not generally considered in routine workup related to cryptogenic stroke. Cureus 2020-07-27 /pmc/articles/PMC7450207/ /pubmed/32864243 http://dx.doi.org/10.7759/cureus.9415 Text en Copyright © 2020, Alhazzaa et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurology
Alhazzaa, Mohammed A
Mujtaba, Ahmed
Aljohani, Mohammed A
Alqarni, Fatimah
Alsharif, Roaa
The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients
title The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients
title_full The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients
title_fullStr The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients
title_full_unstemmed The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients
title_short The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients
title_sort prevalence of fabry disease among young cryptogenic stroke patients
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450207/
https://www.ncbi.nlm.nih.gov/pubmed/32864243
http://dx.doi.org/10.7759/cureus.9415
work_keys_str_mv AT alhazzaamohammeda theprevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients
AT mujtabaahmed theprevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients
AT aljohanimohammeda theprevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients
AT alqarnifatimah theprevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients
AT alsharifroaa theprevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients
AT alhazzaamohammeda prevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients
AT mujtabaahmed prevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients
AT aljohanimohammeda prevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients
AT alqarnifatimah prevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients
AT alsharifroaa prevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients